

CORRECTION

Open Access



Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine

Michael Ament¹, Kathleen Day^{2*}, Virginia L. Stauffer², Vladimir Skljarevski², Mallikarjuna Rettiganti², Eric Pearlman² and Sheena K. Aurora²

Correction to: J Headache Pain 22, 6 (2021)
<https://doi.org/10.1186/s10194-021-01215-9>

Following the publication of the original article [1], the authors have notified us of a few mistakes in Table 1, marked with red below.

Author details

¹Ament Headache Center, Denver, CO 80206, USA. ²Eli Lilly and Company, Indianapolis, IN 46285, USA.

Published online: 26 August 2021

Reference

1. Ament (2021) Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine. *J Headache Pain* 63:22. <https://doi.org/10.1186/s10194-021-01215-9>

The original article can be found online at <https://doi.org/10.1186/s10194-021-01215-9>.

* Correspondence: day_kathleen_ann@lilly.com

²Eli Lilly and Company, Indianapolis, IN 46285, USA

Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Table 1 Baseline demographics and disease characteristics

Variable	EVOLVE-1 and EVOLVE-2 (Episodic Migraine Trials)				REGAIN (Chronic Migraine Trial)			
	PBO N=894	GMB 120 mg N=44 4	GMB 240 mg N=43 5	Total N=177 3	PBO N=558	GMB 120 mg N=278	GMB 240 mg N=277	Total N=1113
Age, years, mean (SD)	41.9 (11.4)	40.9 (11.5)	40.5 (11.2)	41.3 (11.4)	41.6 (12.1)	39.7 (11.9)*	41.1 (12.4)	41.0 (12.1)
Female, n (%)	755 (84.5)	378 (85.1)	366 (84.1)	1499 (84.6)	483 (87)	237 (85)	226(82)	946 (85.0)
Years since migraine diagnosis, mean (SD)	20.5 (12.5)	20.5 (12.3)	19.7 (12.0)	20.3 (12.4)	21.9 (12.9)	20.4 (12.7)	20.1 (12.7)*	21.1 (12.8)*
Number of migraine headache days/month	9.1 (3.0)	9.1 (3.0)	9.1 (2.9)	9.1 (3.0)	19.6 (4.6)	19.4 (4.3)	19.2 (4.6)	19.4 (4.5)
Number of severe migraine headache days/month	2.6 (2.4)	2.5 (2.3)	2.7 (2.3)	2.6 (2.3)	6.6 (5.2)	6.7 (4.9)	6.6 (4.8)	6.6 (5.0)
Number of moderate-severe migraine headache days	7.4 (3.0)	7.4 (3.0)	7.5 (3.1)	7.4 (3.1)	16.1 (5.4)	16.0 (5.2)	15.7 (5.4)	16.0 (5.4)
Mean severity of migraine headache days [‡]	2.1 (0.4)	2.1 (0.4)	2.1 (0.4)	2.1 (0.4)	2.2 (0.4)	2.2 (0.4)	2.2 (0.4)	2.2 (0.4)
Number of migraine headache days with aura	2.6(3.4)	2.3 (3.1)	2.5 (3.3)	2.5 (3.3)	5.0 (6.9)	5.3 (7.3)	4.8 (7.0)	5.0 (7.0)
Number of migraine headache days with nausea and/or vomiting	3.8 (3.2)	3.9 (3.2)	4.0 (3.2)	3.8 (3.2)	9.2 (6.9)	8.8 (6.3)	8.1 (6.5)*	8.8 (6.7)
Number of migraine headache days with photophobia and phonophobia	6.9 (3.7)	6.8 (3.8)	6.8 (3.6)	6.9 (3.7)	15.2 (7.2)	14.8 (7.0)	14.0 (7.6)*	14.8 (7.3)
Number of migraine headache days with prodromal symptoms	3.2 (3.5)	3.2 (3.5)	3.2 (3.4)	3.2 (3.4)	6.8 (7.3)	7.3 (7.5)	7.1 (7.3)	7.0 (7.4)
Proportion of migraine headache days with nausea and vomiting	40.4 (30.1)	41.8 (32.0)	42.3 (30.2)	41.2 (30.6)	46.4 (31.3)	44.7 (29.3)	41.5 (30.3)	44.8 (30.6)
Proportion of migraine headache days with photophobia and phonophobia	74.5 (30.2)	72.8 (31.8)	73.9 (30.7)	73.9 (30.7)	76.4 (29.6)	75.0 (29.7)	71.6 (32.7)	74.8 (30.5)

* $p \leq 0.05$ vs PBO; ** $p \leq 0.01$ vs PBO. [‡]Severity ratings: 1=mild, 2=moderate, 3=severe.

GMB, galcanezumab; PBO, placebo; SD, standard deviation.

* $p \leq 0.05$ vs PBO; ** $p \leq 0.01$ vs PBO. [‡]Severity ratings: 1 = mild, 2 = moderate, 3 = severe
GMB galcanezumab, PBO placebo, SD standard deviation